Caduet and Medrol in line as Hisun-Pfizer China JV kicks off
This article was originally published in Scrip
Executive Summary
Pfizer and partner Zhejiang Hisun Pharmaceutical have formally inaugurated their Chinese joint venture through which both firms are looking to develop sales of off-patent drugs and branded generics mainly in China but also internationally.